If you are:
FDB Only When Necessary: INSUFFICIENT DATA AVAILABLE; NEONATE RISK OF SEIZURES;AVOID DURING 3RD TRIMESTER
Only When Necessary: NEONATAL WITHDRAWAL/RESP.DEPRESS. W/CHRONIC OR HIGH DOSE; SMALL TERATOGENIC RISK
Precaution: MONITOR FOR CHANGES IN RESPIRATION, GI EFFECTS, SEDATION, FEEDING PATTERNS
Precaution: INSUFFICIENT DATA AVAILABLE; MAY CAUSE SEDATION AND INHIBIT LACTATION
An adult over 60:
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
management or monitoring precaution: Pulmonary-Life threatening respiratory depression is more likely to occur with high doses, SR products, cachexia, or debilitation due to altered pharmacokinetics with poor fat stores, muscle wasting, or altered clearance. Monitor closely at initiation and with dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.
Giving tussicaps to a child under 12:
Severe Precaution: Not recommended in children under 6 years unless clinician consultation.
Contraindication: Not recommended in children under 12 years unless clinician consultation.
Contraindication: Risk of respiratory depression, breathing problems. Not for cough suppressant use age < 6 years.
Severe Precaution: Risk of respiratory depression. Caution with use. Weigh risk:benefit.
Contraindication: Possible paradoxical CNS excitation. Seizure risk in newborns.